FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955528799> ?p ?o ?g. }

• W2955528799 endingPage "188" @default.
• W2955528799 startingPage "181" @default.
• W2955528799 abstract "The World Health Organization recently called for the elimination of hepatitis C virus (HCV) and has identified people who inject drugs (PWID) as a key target population. Clinical trials analyzing currently available all-oral regimens have demonstrated a high degree of efficacy in this population, with a relatively low reinfection rate. There is an urgent need to confirm these data in a harm reduction and active consumption setting. The primary aim of this study was to evaluate the HCV reinfection rate in people with recent drug use followed at low-threshold mobile harm reduction units. We included people with recent drug use (smoked or injected heroin/cocaine in the previous 6 months) who received HCV treatment and were attended at two low-threshold mobile harm reduction units over 19 months. Sustained virologic response was assessed 12 weeks after therapy (SVR12). The incidence density of HCV reinfection was defined as the number of reinfections per 100-person years (PY) using person-time of observation and was stratified by drug consumption at initiation of HCV treatment. Cox proportional hazard regression analysis was used to assess factors associated with reinfection. During the study period, 160 people who used drugs in the past 6 months completed HCV therapy. 122 (73.9%) and 88 (53.3%) reported injecting drug use in the 6 months and 30 days prior to HCV treatment, respectively. The overall SVR12 was 68% in the ITT analysis (reinfection = failure) and 90.7% in the modified intent-to-treat analysis (considering reinfections as response and removing people who were missing SVR data). The cohort at-risk for reinfection (n = 121) included 47 (39.2%) people who initiated HCV treatment with recently reported abstinence. Reinfection was identified in 10 persons (8.3%), and the median time to reinfection was 7.2 (IQR 4.2–18) months. Total follow-up time at-risk was 101.1-PY (median 0.6 years, IQR 0.3–1.3). The overall incidence of reinfection was 9.8 per 100-PY (95% CI 4.7,18.2). The incidence of reinfection was higher amongst those who had injected drugs in the previous 6 months (16.7 [95%CI 8.0; 30.7] per 100-PY) and in the previous 30 days (18.9 [95% CI 8.1; 37.2] per 100-PY). In the adjusted analysis, only injecting drugs use in the month prior to initiation of HCV therapy was associated with reinfection (aHR 8.7, 95%CI 1.0; 73.6; p 0.04). High efficacy of HCV treatment, was found in people with recent drug use attended and followed at low-threshold mobile harm reduction units. The high rate of early HCV reinfections in this setting should promote surveillance for reinfection at 7-month intervals after ending the treatment or earlier." @default.
• W2955528799 created "2019-07-12" @default.
• W2955528799 creator A5000395383 @default.
• W2955528799 creator A5037607853 @default.
• W2955528799 creator A5039546959 @default.
• W2955528799 creator A5045823536 @default.
• W2955528799 creator A5060260486 @default.
• W2955528799 creator A5062714976 @default.
• W2955528799 creator A5064746631 @default.
• W2955528799 creator A5064873706 @default.
• W2955528799 creator A5066172430 @default.
• W2955528799 creator A5072414784 @default.
• W2955528799 creator A5083070469 @default.
• W2955528799 creator A5091240405 @default.
• W2955528799 date "2019-10-01" @default.
• W2955528799 modified "2023-10-17" @default.
• W2955528799 title "High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units" @default.
• W2955528799 cites W1096537867 @default.
• W2955528799 cites W1831293561 @default.
• W2955528799 cites W1847544154 @default.
• W2955528799 cites W2027498662 @default.
• W2955528799 cites W2045073898 @default.
• W2955528799 cites W2068027789 @default.
• W2955528799 cites W2074025780 @default.
• W2955528799 cites W2092646281 @default.
• W2955528799 cites W2127548135 @default.
• W2955528799 cites W2135159454 @default.
• W2955528799 cites W2135468595 @default.
• W2955528799 cites W2143398474 @default.
• W2955528799 cites W2146571916 @default.
• W2955528799 cites W2150652264 @default.
• W2955528799 cites W2152072422 @default.
• W2955528799 cites W2258490349 @default.
• W2955528799 cites W2285042371 @default.
• W2955528799 cites W2293959932 @default.
• W2955528799 cites W2307893103 @default.
• W2955528799 cites W2398445701 @default.
• W2955528799 cites W2463563063 @default.
• W2955528799 cites W2518041763 @default.
• W2955528799 cites W2519482181 @default.
• W2955528799 cites W2527949593 @default.
• W2955528799 cites W2539181547 @default.
• W2955528799 cites W2562778217 @default.
• W2955528799 cites W2586742656 @default.
• W2955528799 cites W2588049621 @default.
• W2955528799 cites W2588375831 @default.
• W2955528799 cites W2600141067 @default.
• W2955528799 cites W2610560970 @default.
• W2955528799 cites W2741725136 @default.
• W2955528799 cites W2750028296 @default.
• W2955528799 cites W2751350641 @default.
• W2955528799 cites W2765348434 @default.
• W2955528799 cites W2767298641 @default.
• W2955528799 cites W2784263228 @default.
• W2955528799 cites W2796138741 @default.
• W2955528799 cites W2799828712 @default.
• W2955528799 cites W2800762138 @default.
• W2955528799 cites W2802140772 @default.
• W2955528799 cites W2803289555 @default.
• W2955528799 cites W2884128589 @default.
• W2955528799 cites W2888122510 @default.
• W2955528799 cites W2889967332 @default.
• W2955528799 cites W2900980238 @default.
• W2955528799 cites W2916302288 @default.
• W2955528799 cites W2933695080 @default.
• W2955528799 cites W2938481283 @default.
• W2955528799 cites W4211243282 @default.
• W2955528799 cites W971519378 @default.
• W2955528799 doi "https://doi.org/10.1016/j.drugpo.2019.06.016" @default.
• W2955528799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31253391" @default.
• W2955528799 hasPublicationYear "2019" @default.
• W2955528799 type Work @default.
• W2955528799 sameAs 2955528799 @default.
• W2955528799 citedByCount "28" @default.
• W2955528799 countsByYear W29555287992019 @default.
• W2955528799 countsByYear W29555287992020 @default.
• W2955528799 countsByYear W29555287992021 @default.
• W2955528799 countsByYear W29555287992022 @default.
• W2955528799 countsByYear W29555287992023 @default.
• W2955528799 crossrefType "journal-article" @default.
• W2955528799 hasAuthorship W2955528799A5000395383 @default.
• W2955528799 hasAuthorship W2955528799A5037607853 @default.
• W2955528799 hasAuthorship W2955528799A5039546959 @default.
• W2955528799 hasAuthorship W2955528799A5045823536 @default.
• W2955528799 hasAuthorship W2955528799A5060260486 @default.
• W2955528799 hasAuthorship W2955528799A5062714976 @default.
• W2955528799 hasAuthorship W2955528799A5064746631 @default.
• W2955528799 hasAuthorship W2955528799A5064873706 @default.
• W2955528799 hasAuthorship W2955528799A5066172430 @default.
• W2955528799 hasAuthorship W2955528799A5072414784 @default.
• W2955528799 hasAuthorship W2955528799A5083070469 @default.
• W2955528799 hasAuthorship W2955528799A5091240405 @default.
• W2955528799 hasConcept C120665830 @default.
• W2955528799 hasConcept C121332964 @default.
• W2955528799 hasConcept C126322002 @default.
• W2955528799 hasConcept C138816342 @default.
• W2955528799 hasConcept C142724271 @default.
• W2955528799 hasConcept C167704817 @default.

• next